Add Trial
Sign In

KEYNOTE-598 / MK-3475-598 - Hosted By

Sponsor Name
Tumor Site NSCLC - Non Small Cell Lung Cancer
Disease Stage Stage IV
Clinical Status Advanced Disease 1st Line
Phase Phase III
Intervention / Treatment Pembrolizumab + Ipilimumab vs Ipilumumab + Placebo
Research Site Montreal, QC, St. Mary's Hospital
Investigator Dr Adrian Langleben
Telephone Number +1 (514) 345-3511
Study Start Date October 5, 2017
Study End Date February 22, 2024
Trial Status Recruitment Complete


Working Hours :

Now Closed UTC - 4
  • MondayDay Off
  • TuesdayDay Off
  • WednesdayDay Off
  • ThursdayDay Off
  • FridayDay Off
  • SaturdayDay Off
  • SundayDay Off

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

More from this author :

Claim listing: KEYNOTE-598 / MK-3475-598

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Please select an account type above.

Account details will be confirmed via email.

Register with us by filling out the form below.
Register with us by filling out the form below.

Reset Your Password